×
COMPASS Pathways ( CMPS ) enters the comparison with positive Phase 3 data and an imminent New Drug Application (NDA) filing, while Bright Minds Biosciences ( DRUG ) is absorbing an FDA partial clinical hold on its lead Phase 2 program. The two names sit at opposite ends of the clinical-stage risk spectrum: CMPS is preparing for potential commercialization, while DRUG faces a development timeline that is likely to be delayed.
COMPASS Pathways ( CMPS ) is advancing a late-stage psilocybin therapy with positive Phase 3 data and an active regulatory filing, while Neumora Therapeutics ( NMRA ) has reset to an earlier-stage pipeline after its lead program failed in Phase 3. Relative performance has diverged sharply: CMPS has gained substantially over the past year, whereas NMRA trades near its lows following a series of clinical setbacks.
Tickeron AI Verdict: Based on observable trend consistency, momentum, and catalysts, Tickeron's AI currently leans toward THC over HCA . HCA brings unmatched scale and stability, while THC offers faster recent momentum and a beat-and-raise earnings pattern.
ABBV (AbbVie) trades near record highs after a strong quarter, supported by double-digit revenue growth, a raised outlook, and a dividend increase. ADUS (Addus HomeCare) reached a fresh 52-week high, with acquisition-driven expansion and steady home-care demand as key catalysts.
NIVF dropped -15.79% to $0.96 from a prior close of $1.14, with the decline occurring during the regular trading session. No verified news or fundamental catalyst found. Consistent with continued speculative selling in a heavily diluted micro-cap that executed a 1-for-8 reverse split on Oct. 23 and filed a $100M shelf registration on Oct. 27.
Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million , up 1.7% year over year and slightly above analyst consensus estimates. Adjusted earnings per share (EPS) came in at $0.72 , beating consensus estimates of roughly $0.65 and rising from $0.67 in the prior-year quarter.
Option Care Health is scheduled to report its third quarter 2026 results, for the period ended September 30, 2026, on November 4, 2026, before the market opens. Consensus estimates point to earnings of approximately $0.44 per share, according to data tracked by EarningsWhispers.
DaVita reported third-quarter 2026 revenue of approximately $3.58 billion , up about 4.6% year over year and slightly ahead of consensus estimates. Adjusted diluted earnings per share (EPS) came in at $3.82 , beating analyst expectations, while GAAP (Generally Accepted Accounting Principles) EPS of $3.40 reflected one-time charges.
Tenet Healthcare reported third-quarter 2026 net operating revenues of $5.63 billion, up 6.5% year over year and above analyst consensus estimates. Adjusted diluted earnings per share (EPS) rose 79.5% to $6.64, well ahead of Wall Street expectations of roughly $4.60 to $4.68 per share.
CYH fell -15.04%, trading around $2.26 versus the prior close of $2.66, with the slide unfolding in after-hours and premarket trading. The drop follows a Q3 2026 double miss: adjusted EPS of -$0.48 versus roughly -$0.22 expected, and revenue of ~$2.76B missing the ~$2.8B consensus.
DVA (DaVita) and KIM (Kimco Realty) operate in unrelated sectors, yet both posted earnings beats and raised full-year guidance in their most recent reporting periods, supporting constructive sentiment across each name. DVA has displayed stronger price momentum, with a sharp post-earnings surge and a year-to-date advance that has meaningfully outpaced the broader market, while KIM has delivered steadier, income-oriented performance.
Community Health Systems (NYSE: CYH) reported a net loss attributable to stockholders of $86 million, or $0.63 per share, in the third quarter of 2026, swinging from net income of $130 million, or $0.96 per share, a year earlier. Adjusted earnings per share (EPS) came in at a loss of $0.48, missing the consensus estimate of roughly a $0.29 loss.
Encompass Health reported third-quarter 2026 net operating revenue of $1.61 billion, up 8.9% year over year (YoY). Adjusted earnings per share (EPS) came in at $1.52, comfortably above the Wall Street consensus estimate of $1.36.
Upcoming earnings catalyst: Strata Critical Medical's next quarterly report is expected around early November 2026, giving investors a fresh read on the integration of the Keystone Perfusion Services acquisition and progress toward profitability. Strategic repositioning: Following the divestiture of its passenger business to Joby Aviation, SRTA is now a focused, pure-play provider of time-critical organ logistics and transplant clinical services across the United States.
The central stock price target of $9.50 is the rounded arithmetic mean of four current analyst price targets, which average roughly $9.56. The analyst range is wide, from $8.00 to $12.75 , with a consensus "Strong Buy" rating.
Strata Critical Medical (SRTA) shares have slipped roughly 9.6% over the trailing 30 days, from about $5.23 to near $4.73, reflecting continued post-divestiture repricing rather than a single sharp catalyst. Activist investor Third Point disclosed a 5.8% stake in mid-October 2026 and urged the board to explore strategic alternatives, including a possible sale, lifting shares about 5% on the disclosure.
Chemed reported third-quarter 2026 revenue of $690.9 million , up 10.6% from $624.9 million a year earlier. Adjusted (non-GAAP) earnings per share (EPS) came in at $6.75 , beating the consensus estimate of $6.44 by about 4.9%.
Net revenue rose 5.3% year over year to $4.73 billion , roughly in line with analyst consensus of about $4.71 billion. Adjusted earnings per share (EPS, a measure of profit allocated to each share) came in at $5.22 , edging past the consensus estimate of approximately $5.15 but down from $5.69 a year earlier.
HCA Healthcare shares have advanced roughly 8% over the trailing 30 days, a steady climb that leaves the stock well above its 52-week low of about $354 and below its 52-week high near $556. As of late October 2026, HCA traded around $472 per share, with a market capitalization of approximately $101 billion and a price-to-earnings ratio in the mid-teens.
AUNA fell -14.60% intraday to $4.62 from a $5.41 prior close, with the selloff starting in premarket trading. Primary catalyst: the company slashed 2026 adjusted EBITDA guidance to "broadly stable" YoY, down from prior 10%–14% FX-neutral growth.